Literature DB >> 28951977

Polycystic ovary syndrome throughout a woman's life.

José Bellver1, Luis Rodríguez-Tabernero2, Ana Robles3, Elkin Muñoz4, Francisca Martínez5, José Landeras6, Juan García-Velasco7, Juan Fontes8, Mónica Álvarez9, Claudio Álvarez10, Belén Acevedo11.   

Abstract

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder among reproductive-aged women and the main cause of infertility due to anovulation. However, this syndrome spans the lives of women affecting them from in-utero life until death, leading to several health risks that can impair quality of life and increase morbidity and mortality rates. Fetal programming may represent the beginning of the condition characterized by hyperandrogenism and insulin resistance which leads to a series of medical consequences in adolescence, adulthood, and old age. Menstrual and fertility problems evolve into metabolic complications as age advances. An early and precise diagnosis is important for an adequate management of PCOS, especially at the extreme ends of the reproductive lifespan. However, many different phenotypes are included under the same condition, being important to look at these different phenotypes separately, as they may require different treatments and have different consequences. In this way, PCOS exhibits a great metabolic complexity and its diagnosis needs to be revised once again and adapted to recent data obtained by new technologies. According to the current medical literature, lifestyle therapy constitutes the first step in the management, especially when excess body weight is associated. Pharmacotherapy is frequently used to treat the most predominant manifestations in each age group, such as irregular menses and hirsutism in adolescence, fertility problems in adulthood, and metabolic problems and risk of cancer in old age. Close surveillance is mandatory in each stage of life to avoid health risks which may also affect the offspring, since fetal and post-natal complications seem to be increased in PCOS women.

Entities:  

Keywords:  Adolescence; Childhood; Fertility; Perimenopause; Polycystic ovary syndrome; Pregnancy complications

Mesh:

Year:  2017        PMID: 28951977      PMCID: PMC5758469          DOI: 10.1007/s10815-017-1047-7

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  132 in total

1.  Agonist trigger: what is the best approach? Agonist trigger with vitrification of oocytes or embryos.

Authors:  Juan A Garcia-Velasco
Journal:  Fertil Steril       Date:  2012-01-04       Impact factor: 7.329

Review 2.  Avoiding ovarian hyperstimulation syndrome with the use of gonadotropin-releasing hormone agonist trigger.

Authors:  Human Mousavi Fatemi; Juan Garcia-Velasco
Journal:  Fertil Steril       Date:  2015-02-24       Impact factor: 7.329

3.  The Diagnosis of Polycystic Ovary Syndrome during Adolescence.

Authors:  Selma F Witchel; Sharon Oberfield; Robert L Rosenfield; Ethel Codner; Andrea Bonny; Lourdes Ibáñez; Alexia Pena; Reiko Horikawa; Veronica Gomez-Lobo; Dipesalema Joel; Hala Tfayli; Silva Arslanian; Preeti Dabadghao; Cecilia Garcia Rudaz; Peter A Lee
Journal:  Horm Res Paediatr       Date:  2015-04-01       Impact factor: 2.852

4.  Epidemiology and comorbidities of polycystic ovary syndrome in an indigent population.

Authors:  Susan M Sirmans; Roy C Parish; Sandra Blake; Xiaojun Wang
Journal:  J Investig Med       Date:  2014-08       Impact factor: 2.895

Review 5.  Hormonal alterations in PCOS and its influence on bone metabolism.

Authors:  Abhaya Krishnan; Sridhar Muthusami
Journal:  J Endocrinol       Date:  2016-11-28       Impact factor: 4.286

6.  Molecular abnormalities in oocytes from women with polycystic ovary syndrome revealed by microarray analysis.

Authors:  Jennifer R Wood; Daniel A Dumesic; David H Abbott; Jerome F Strauss
Journal:  J Clin Endocrinol Metab       Date:  2006-12-05       Impact factor: 5.958

7.  Placental STAT3 signaling is activated in women with polycystic ovary syndrome.

Authors:  M Maliqueo; I Sundström Poromaa; E Vanky; R Fornes; A Benrick; H Åkerud; S Stridsklev; F Labrie; T Jansson; E Stener-Victorin
Journal:  Hum Reprod       Date:  2015-01-20       Impact factor: 6.918

Review 8.  Premature adrenarche: novel lessons from early onset androgen excess.

Authors:  Jan Idkowiak; Gareth G Lavery; Vivek Dhir; Timothy G Barrett; Paul M Stewart; Nils Krone; Wiebke Arlt
Journal:  Eur J Endocrinol       Date:  2011-05-26       Impact factor: 6.664

Review 9.  Extra- and intra-ovarian factors in polycystic ovary syndrome: impact on oocyte maturation and embryo developmental competence.

Authors:  Jie Qiao; Huai L Feng
Journal:  Hum Reprod Update       Date:  2010-07-16       Impact factor: 15.610

Review 10.  Genetic, hormonal and metabolic aspects of PCOS: an update.

Authors:  V De Leo; M C Musacchio; V Cappelli; M G Massaro; G Morgante; F Petraglia
Journal:  Reprod Biol Endocrinol       Date:  2016-07-16       Impact factor: 5.211

View more
  31 in total

1.  First ovarian response to gonadotrophin stimulation in rats exposed to neonatal androgen excess.

Authors:  Rebeca Chávez-Genaro; Gabriel Anesetti
Journal:  J Mol Histol       Date:  2018-10-09       Impact factor: 2.611

2.  Chronic Estrus Disrupts Uterine Gland Development and Homeostasis.

Authors:  C Allison Stewart; M David Stewart; Ying Wang; Rachel D Mullen; Bonnie K Kircher; Rui Liang; Yu Liu; Richard R Behringer
Journal:  Endocrinology       Date:  2022-03-01       Impact factor: 4.736

3.  Dietary Patterns and Polycystic Ovary Syndrome: a Systematic Review.

Authors:  Maria Xenou; Kleanthi Gourounti
Journal:  Maedica (Bucur)       Date:  2021-09

Review 4.  Polycystic ovarian syndrome and miscarriage in IVF: systematic revision of the literature and meta-analysis.

Authors:  Roberto Matorras; Jose Ignacio Pijoan; Lucía Laínz; María Díaz-Nuñez; Héctor Sainz; Silvia Pérez-Fernandez; Dayana Moreira
Journal:  Arch Gynecol Obstet       Date:  2022-09-04       Impact factor: 2.493

5.  Long non-coding RNA HLA-F antisense RNA 1 inhibits the maturation of microRNA-613 in polycystic ovary syndrome to promote ovarian granulosa cell proliferation and inhibit cell apoptosis.

Authors:  Xiaohua Li; Laifang Zhu; Yan Luo
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

6.  Comparison of metabolic and obesity biomarkers between adolescent and adult women with polycystic ovary syndrome.

Authors:  Sebastião Freitas de Medeiros; Matheus Antônio Souto de Medeiros; Bruna Barcelo Barbosa; Márcia Marly Winck Yamamoto; Gustavo Arantes Rosa Maciel
Journal:  Arch Gynecol Obstet       Date:  2020-11-17       Impact factor: 2.344

7.  Circular RNA expression profiling in the fetal side of placenta from maternal polycystic ovary syndrome and circ_0023942 inhibits the proliferation of human ovarian granulosa cell.

Authors:  Chengcheng Zhao; Yu Zhou; Xia Shen; Min Gong; Yingfei Lu; Chao Fang; Jianquan Chen; Rong Ju
Journal:  Arch Gynecol Obstet       Date:  2020-03-19       Impact factor: 2.344

8.  Inhibition of sestrin 1 alleviates polycystic ovary syndrome by decreasing autophagy.

Authors:  Xiaoyuan Xu; Xinli Song; Xiaohua Xu; Yanluan Zheng; Lan Xu; Ling Shen
Journal:  Aging (Albany NY)       Date:  2021-04-22       Impact factor: 5.682

Review 9.  Natural Molecules in the Management of Polycystic Ovary Syndrome (PCOS): An Analytical Review.

Authors:  Matteo Iervolino; Elisa Lepore; Gianpiero Forte; Antonio Simone Laganà; Giovanni Buzzaccarini; Vittorio Unfer
Journal:  Nutrients       Date:  2021-05-15       Impact factor: 5.717

10.  A Pilot Trial: Fish Oil and Metformin Effects on ApoB-Remnants and Triglycerides in Women With Polycystic Ovary Syndrome.

Authors:  Donna Vine; Ethan Proctor; Olivia Weaver; Mahua Ghosh; Katerina Maximova; Spencer Proctor
Journal:  J Endocr Soc       Date:  2021-06-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.